The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Anticancer strategies involving the vasculature
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This normalization involves the pruning and remodeling of the tumor vasculature so that it more closely resembles normal vasculature”
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Molecular regulation of angiogenesis and lymphangiogenesis
Adams, R. H., & Alitalo, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2183 · Cited by 2,019
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Fibronectins: multifunctional modular glycoproteins.
Hynes, R. O., & Yamada, K. M. (1982) · The Journal of cell biology · doi:10.1083/jcb.95.2.369 · Cited by 1,326
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Protein Tyrosine Kinase Structure and Function
Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,171
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists
Dechantsreiter, M. A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S. L., & Kessler, H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm970832g · Cited by 838
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Self-citationChang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Endothelial cell diversity revealed by global expression profiling
Chi, J.-T., Chang, H. Y., Haraldsen, G., Jahnsen, F. L., Troyanskaya, O. G., Chang, D. S., Wang, Z., Rockson, S. G., van de Rijn, M., Botstein, D., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434429100 · Cited by 771
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Eliceiri, B. P., & Cheresh, D. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6869 · Cited by 649
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., & Ferrara, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002016200 · Cited by 620
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Self-citationVascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Abramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Ran, S., Downes, A., & Thorpe, P. E. (2002) · PubMed · Cited by 471
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 422
Genes that Distinguish Physiological and Pathological Angiogenesis
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., & St. Croix, B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.017 · Cited by 419
Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance
Burri, P. H., Hlushchuk, R., & Djonov, V. (2004) · Developmental Dynamics · doi:10.1002/dvdy.20184 · Cited by 413
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 351
Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., & Baralle, F. E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02509.x · Cited by 338
Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., & Natali, P. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.3.1139 · Cited by 335
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., et al. (2003) · PubMed · Cited by 335
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Brekken, R. A., Overholser, J. P., Stastny, V., Waltenberger, J. L., Minna, J. D., & Thorpe, P. E. (2000) · PubMed · Cited by 331
Huminiecki, L., Gorn, M., Suchting, S., Poulsom, R., & Bicknell, R. (2002) · Genomics · doi:10.1006/geno.2002.6745 · Cited by 329
Self-citationThe fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Vascular‐targeting therapies for treatment of malignant disease
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2004) · Cancer · doi:10.1002/cncr.20299 · Cited by 310
Kanthou, C., & Tozer, G. M. (2002) · Blood · doi:10.1182/blood.v99.6.2060 · Cited by 280
Horowitz, J. R., Rivard, A., van der Zee, R., Hariawala, M., Sheriff, D. D., Esakof, D. D., Chaudhry, G. M., Symes, J. F., & Isner, J. M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2793 · Cited by 266
Lippert, J. W. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.020 · Cited by 247
MacDonald, T. J., Taga, T., Shimada, H., Tabrizi, P., Zlokovic, B. V., Cheresh, D. A., & Laug, W. E. (2001) · Neurosurgery · doi:10.1097/00006123-200101000-00026 · Cited by 240
Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis
Larrivée, B., Freitas, C., Trombe, M., Lv, X., DeLafarge, B., Yuan, L., Bouvrée, K., Bréant, C., Del Toro, R., Bréchot, N., et al. (2007) · Genes & Development · doi:10.1101/gad.437807 · Cited by 239
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 217
Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., & Ellis, L. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0693fje · Cited by 214
Reardon, D. A., Nabors, L. B., Stupp, R., & Mikkelsen, T. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1225 · Cited by 206
Gilliland, D. G., & Griffin, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00003 · Cited by 202
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.
Burrows, F. J., & Thorpe, P. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.8996 · Cited by 198
Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C
Brack, S. S., Silacci, M., Birchler, M., & Neri, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2804 · Cited by 176
Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration
Suchting, S., Heal, P., Tahtis, K., Stewart, L. M., & Bicknell, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-1991fje · Cited by 169
Self-citationSeon, B. K., Matsuno, F., Haruta, Y., Kondo, M., & Barcos, M. P. (1997) · PubMed · Cited by 166
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression
HEROULT, M., SCHAFFNER, F., & AUGUSTIN, H. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.028 · Cited by 160
Molecular mechanisms of tumor vascularization
Auguste, P., Lemière, S., Larrieu-Lahargue, F., & Bikfalvi, A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.11.006 · Cited by 156
In Silico Cloning of Novel Endothelial-Specific GenesPreprint
Huminiecki, Ł. (2000) · Genome Research · doi:10.1101/gr.150700 · Cited by 146
Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 145
Duda, D. G., Jain, R. K., & Willett, C. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3985 · Cited by 142
Rusnati, M., & Presta, M. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781039689 · Cited by 141
Cooney, M. M., Radivoyevitch, T., Dowlati, A., Overmoyer, B. A., Levitan, N. I., Robertson, K., Levine, S. L., DeCaro, K., Buchter, C. M., Taylor, A. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0364-3 · Cited by 135
Delta-like 4/Notch Signaling and Its Therapeutic Implications
Yan, M., & Plowman, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1393 · Cited by 129
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer
Lodish, M. B., & Stratakis, C. A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.625 · Cited by 126
Carnemolla, B., Castellani, P., Ponassi, M., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65388-6 · Cited by 121
Beerepoot, L. V., Radema, S. A., Witteveen, E. O., Thomas, T., Wheeler, C., Kempin, S. J., & Voest, E. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7458 · Cited by 115
Siemann, D. W., & Shi, W. (2008) · Anticancer Research · Cited by 105
He, J., Luster, T. A., & Thorpe, P. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0793 · Cited by 93
Akabani, G., Reardon, D. A., Coleman, R. E., Wong, T. Z., Metzler, S. D., Bowsher, J. E., Barboriak, D. P., Provenzale, J. M., Greer, K. L., DeLong, D. M., et al. (2005) · PubMed · Cited by 93
Castronovo, V., Waltregny, D., Kischel, P., Roesli, C., Elia, G., Rybak, J., & Neri, D. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600164-mcp200 · Cited by 91
A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer
Mauer, A. M., Cohen, E. E. W., Ma, P. C., Kozloff, M. F., Schwartzberg, L. S., Coates, A., Qian, J. X., Hagey, A. E., & Gordon, G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e01f · Cited by 90
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients
Reardon, D. A., Zalutsky, M. R., & Bigner, D. D. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.675 · Cited by 75
Hua, J., Sheng, Y., Pinney, K. G., Garner, C. M., Kane, R. R., Prezioso, J. A., Pettit, G. R., Chaplin, D. J., & Edvardsen, K. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80778-x · Cited by 66
Huang, X., Bennett, M. A., & Thorpe, P. E. (2004) · The Prostate · doi:10.1002/pros.20074 · Cited by 63
Herbert, J. M. J., Stekel, D. J., Sanderson, S., Heath, V. L., & Bicknell, R. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-153 · Cited by 63
Self-citationVascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Riely, G. J., & Miller, V. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0544 · Cited by 59
New approaches in angiogenic targeting for colorectal cancer
Prat, A., Casado, E., & Cortés, J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5857 · Cited by 58
Hanrahan, E. O., & Heymach, J. V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0539 · Cited by 48
Rizzieri, D. A., Akabani, G., Zalutsky, M. R., Coleman, R. E., Metzler, S. D., Bowsher, J. E., Toaso, B., Anderson, E. L., Lagoo, A. S., Clayton, S., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4264 · Cited by 47
Taguchi, E., Nakamura, K., Miura, T., Shibuya, M., & Isoe, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00724.x · Cited by 35
Castronovo, V., Kischel, P., Guillonneau, F., de Leval, L., Deféchereux, T., Pauw, E. D., Neri, D., & Waltregny, D. (2007) · PROTEOMICS · doi:10.1002/pmic.200600888 · Cited by 32
Wakai, Y., Matsui, J., Koizumi, K., Tsunoda, S., Makimoto, H., Ohizumi, I., Taniguchi, K., Kaiho, S.-I., Saito, H., Utoguchi, N., et al. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00920.x · Cited by 20
The Potential of New Tumor Endothelium-Specific Markers for the Development of Antivascular Therapy
Li, J., & Harris, A. L. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.004 · Cited by 19
Cited by
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Oxidative stress in angiogenesis and vascular disease
Kim, Y.-W., & Byzova, T. V. (2014) · Blood · doi:10.1182/blood-2013-09-512749 · Cited by 701
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“Successful therapy—but challenges remain Bevacizumab was the first molecular-targeted antiangiogenic therapy approved by the FDA and is used as first-line therapy in colorectal cancer (CRC), metastatic breast cancer (MBC), non-small-cell lung cancer (NSCLC), and metastatic renal cell carcinoma (mRCC), and as second-li…”
BackgroundSiemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Metadata
- Authors
- Heath, V. L., & Bicknell, R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-05-07
- Volume
- 6
- Issue
- 7
- Pages
- 395-404
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1969950242
- Cited by
- 255
- References
- 94
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.